Neurocrine Biosciences (NBIX) News Today $115.60 +3.68 (+3.29%) Closing price 04:00 PM EasternExtended Trading$115.06 -0.54 (-0.47%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Summit Global Investments Lowers Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Summit Global Investments lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,060 shares of the company's stockMarch 23 at 5:50 AM | marketbeat.comNatixis Advisors LLC Has $4.59 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Natixis Advisors LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 14.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,604 shares of theMarch 23 at 3:54 AM | marketbeat.comVinva Investment Management Ltd Has $1.82 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Vinva Investment Management Ltd lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 65.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,291 shares of the company's stock afteMarch 22 at 5:02 AM | marketbeat.comNeurocrine’s ingrezza shows efficacy in tardive dyskinesia studyMarch 21 at 6:44 AM | markets.businessinsider.comGenerali Asset Management SPA SGR Makes New $3.22 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Generali Asset Management SPA SGR purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,605 shares of the company's stock, valuedMarch 21 at 5:05 AM | marketbeat.comNeurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) CapsulesMarch 20, 2025 | prnewswire.comFirst Financial Bankshares Inc Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)First Financial Bankshares Inc raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 51.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,942 shares of the company's stock after buying an additional 9March 20, 2025 | marketbeat.comThrivent Financial for Lutherans Purchases 711,970 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Thrivent Financial for Lutherans lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2,759.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 737,772 shares of the company'March 20, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by StockNews.comStockNews.com cut shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Thursday.March 20, 2025 | marketbeat.comPrimecap Management Co. CA Sells 10,290 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Primecap Management Co. CA lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 393,710 shares of the company's stock after seMarch 19, 2025 | marketbeat.comNeurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comIs Neurocrine Biosciences, Inc. (NBIX) a Best Biotech Stock According to Billionaires?March 18, 2025 | msn.comProficio Capital Partners LLC Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Proficio Capital Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 34,535 shares of the company'March 18, 2025 | marketbeat.comBillionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 StocksMarch 17, 2025 | 247wallst.comNeurocrine presents new KINECT-HD dataMarch 17, 2025 | markets.businessinsider.comNeurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) CapsulesMarch 17, 2025 | prnewswire.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Lbp Am SaLbp Am Sa trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,133 shares of the company's stock after selling 4,733 sharesMarch 17, 2025 | marketbeat.comSwiss National Bank Sells 13,400 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Swiss National Bank lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 285,300 shares of the company's stock after selling 13,March 17, 2025 | marketbeat.comGreat Lakes Advisors LLC Sells 5,832 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Great Lakes Advisors LLC trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 56.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,575 shares of the company'March 17, 2025 | marketbeat.comTredje AP fonden Decreases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Tredje AP fonden lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 50.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,364 shares of the company's stock after selling 9,364 shares duringMarch 16, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 270.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,582 shaMarch 16, 2025 | marketbeat.comAGF Management Ltd. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)AGF Management Ltd. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,633 shares of the compMarch 16, 2025 | marketbeat.comWealthfront Advisers LLC Buys New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Wealthfront Advisers LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,382 shares of the company's stock, valued atMarch 16, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Daiwa Securities Group Inc.Daiwa Securities Group Inc. reduced its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 30.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,160 shares of the company's stock after selMarch 16, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $24.73 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Skandinaviska Enskilda Banken AB publ cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 180,406March 15, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Strong-Buy at StockNews.comMarch 15, 2025 | americanbankingnews.comNeurocrine Biosciences (NASDAQ:NBIX) Upgraded by StockNews.com to Strong-Buy RatingStockNews.com raised shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research note on Wednesday.March 13, 2025 | marketbeat.comAmundi Sells 394,835 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Amundi reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 60.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 261,860 shares of the company's stock after selling 394,835 sMarch 13, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Sets New 52-Week Low - Here's WhyNeurocrine Biosciences (NASDAQ:NBIX) Sets New 52-Week Low - Time to Sell?March 12, 2025 | marketbeat.comNeurocrine price target lowered to $139 from $148 at RBC CapitalMarch 11, 2025 | markets.businessinsider.comNeurocrine Biosciences to Present at the Stifel 2025 Virtual CNS ForumMarch 11, 2025 | prnewswire.comEdgestream Partners L.P. Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Edgestream Partners L.P. raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 138.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,574 shares of the company's stockMarch 11, 2025 | marketbeat.comVictory Capital Management Inc. Sells 14,309 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Victory Capital Management Inc. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 189,896 shares of the company's stoMarch 11, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 762,557 shares of the company's stock after acquiring an additMarch 10, 2025 | marketbeat.comAndra AP fonden Sells 77,600 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Andra AP fonden decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 43.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 100,300 shares of the company's stock aMarch 9, 2025 | marketbeat.comRaymond James Financial Inc. Invests $115.19 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Raymond James Financial Inc. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 843,902 shares of the company'sMarch 9, 2025 | marketbeat.comNeurocrine Biosciences' (NBIX) "Overweight" Rating Reaffirmed at Morgan StanleyMorgan Stanley reaffirmed an "overweight" rating and set a $150.00 price target (down from $185.00) on shares of Neurocrine Biosciences in a research note on Friday.March 8, 2025 | marketbeat.comNeurocrine assumed with an Overweight at Morgan StanleyMarch 7, 2025 | markets.businessinsider.comPositive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales ProjectionsMarch 7, 2025 | tipranks.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Candriam S.C.A.Candriam S.C.A. cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 37.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 303,972 shares of the company's stock after selling 179,269 shareMarch 7, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Sees Large Increase in Short InterestNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 3,040,000 shares, an increase of 26.7% from the January 31st total of 2,400,000 shares. Based on an average daily volume of 1,180,000 shares, the days-to-cover ratio is presently 2.6 days.March 6, 2025 | marketbeat.comVanguard Group Inc's Strategic Acquisition of Neurocrine Biosciences SharesMarch 6, 2025 | gurufocus.comNeurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological ConditionsMarch 6, 2025 | finance.yahoo.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from AnalystsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, seventeen have issueMarch 6, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Medios AG (OtherMEDOF)March 5, 2025 | markets.businessinsider.comNeurocrine begins Phase 1 clinical study of NBI-1140675March 5, 2025 | markets.businessinsider.comNeurocrine Biosciences (NASDAQ:NBIX) Reaches New 12-Month Low - What's Next?Neurocrine Biosciences (NASDAQ:NBIX) Hits New 52-Week Low - Here's WhyMarch 5, 2025 | marketbeat.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy AdultsMarch 5, 2025 | prnewswire.comFisher Asset Management LLC Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Fisher Asset Management LLC raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 34.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,104 shares of the companyMarch 4, 2025 | marketbeat.comProficio Capital Partners LLC Invests $4.71 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Proficio Capital Partners LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 34,535 shares of the company's stock, valued at approximateMarch 4, 2025 | marketbeat.com Remove Ads Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.230.64▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼1314▲NBIX Articles Average Week Remove Ads Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today BioMarin Pharmaceutical News Today Incyte News Today Exelixis News Today Repligen News Today Exact Sciences News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThis could put Trump on new $100 billAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts